Publications

2019

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;116(23):11428-11436.
Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, et al. TKI-resistant -rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations. Lung Cancer (Auckl). 2019;10:81-86.
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408-412.
Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2019.
Sfeir MM, Hayden JA, Fauntleroy KA, Mazur C, Johnson JK, Simner PJ, et al. EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β-Lactamase-Producing . J Clin Microbiol. 2019;57(5).

2018

Fan J, Wei Q, Koay EJ, Liu Y, Ning B, Bernard PW, et al. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. Theranostics. 2018;8(21):5986-5994.
van der Touw W, Kang K, Luan Y, Ma G, Mai S, Qin L, et al. Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B. J Immunol. 2018;201(6):1727-1734.
Larimer BM, Dubois F, Bloch E, Nesti S, Placzek M, Zadra G, et al. Specific F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone-Binding Globulin. J Nucl Med. 2018;59(10):1538-1543.
Massonneau J, Ouellet C, Lucien F, Dubois CM, Tyler J, Boissonneault G. Suboptimal extracellular pH values alter DNA damage response to induced double-strand breaks. FEBS Open Bio. 2018;8(3):416-425.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700